On Monday, Aclaris Therapeutics Inc (NASDAQ: ACRS) opened higher 6.25% from the last session, before settling in for the closing price of $2.72. Price fluctuations for ACRS have ranged from $0.86 to $5.17 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 74.29% over the last five years. Company’s average yearly earnings per share was noted 35.83% at the time writing. With a float of $59.91 million, this company’s outstanding shares have now reached $71.42 million.
The firm has a total of 91 workers. Let’s measure their productivity. In terms of profitability, gross margin is 53.53%, operating margin of -150.31%, and the pretax margin is -138.0%.
Aclaris Therapeutics Inc (ACRS) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Diagnostics & Research industry is another important factor to consider. The insider ownership of Aclaris Therapeutics Inc is 16.13%, while institutional ownership is 75.64%. The most recent insider transaction that took place on Nov 19 ’24, was worth 1,499,998. In this transaction Director of this company bought 666,666 shares at a rate of $2.25, taking the stock ownership to the 710,030 shares. Before that another transaction happened on Aug 05 ’24, when Company’s 10% Owner bought 206,025 for $1.24, making the entire transaction worth $256,357. This insider now owns 14,250,000 shares in total.
Aclaris Therapeutics Inc (ACRS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 35.83% per share during the next fiscal year.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Check out the current performance indicators for Aclaris Therapeutics Inc (ACRS). In the past quarter, the stock posted a quick ratio of 7.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.52, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -0.59 in one year’s time.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
Analysing the last 5-days average volume posted by the [Aclaris Therapeutics Inc, ACRS], we can find that recorded value of 1.3 million was lower than the volume posted last year of 1.39 million. As of the previous 9 days, the stock’s Stochastic %D was 6.84%. Additionally, its Average True Range was 0.35.
During the past 100 days, Aclaris Therapeutics Inc’s (ACRS) raw stochastic average was set at 43.70%, which indicates a significant increase from 13.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.76% in the past 14 days, which was lower than the 122.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.70, while its 200-day Moving Average is $1.58. Now, the first resistance to watch is $3.06. This is followed by the second major resistance level at $3.23. The third major resistance level sits at $3.34. If the price goes on to break the first support level at $2.78, it is likely to go to the next support level at $2.67. Now, if the price goes above the second support level, the third support stands at $2.50.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Key Stats
There are currently 71,431K shares outstanding in the company with a market cap of 206.44 million. Presently, the company’s annual sales total 31,250 K according to its annual income of -88,480 K. Last quarter, the company’s sales amounted to 4,350 K and its income totaled -7,590 K.
